Search Results - "Lostakova, Vladimira"
-
1
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
Published in Respiratory research (21-01-2019)“…Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the…”
Get full text
Journal Article -
2
Adherence to the ISHLT Protocol for the Referral of Patients with Idiopathic Pulmonary Fibrosis to the Transplantation Center among of Czech Centers for Interstitial Lung Diseases
Published in Pulmonary medicine (30-06-2024)“…There are limited data on referral rates and the number of patients with idiopathic pulmonary fibrosis (IPF) who are eligible for lung transplantation. The aim…”
Get full text
Journal Article -
3
The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
Published in BMC pulmonary medicine (03-05-2023)“…The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic…”
Get full text
Journal Article -
4
An effect of the outpatient rehabilitation programme in patients with chronic respiratory diseases
Published in Acta Universitatis Palackianae Olomucensis. Gymnica (01-01-2013)“…BACKGROUND: Pulmonary rehabilitation is a common type of complex treatment especially in patients with chronic obstructive pulmonary disease (COPD). By…”
Get full text
Journal Article -
5
DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study
Published in Therapeutic advances in respiratory disease (2021)“…Background: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of…”
Get full text
Journal Article -
6
EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis
Published in The clinical respiratory journal (01-04-2018)“…Prognostic factors of idiopathic pulmonary fibrosis (IPF) currently recognized include changes in vital capacity and radiologic findings. However, most of the…”
Get more information
Journal Article -
7
Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations
Published in Frontiers in immunology (11-07-2016)“…Idiopathic pulmonary fibrosis (IPF) affects lung parenchyma with progressing fibrosis. In this study, we aimed to replicate MUC5B rs35705950 variants and…”
Get full text
Journal Article -
8
rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study
Published in Therapeutic advances in respiratory disease (01-09-2021)“…Background: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of…”
Get full text
Journal Article -
9
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis
Published in Respiratory research (08-01-2020)“…Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of…”
Get full text
Journal Article -
10
Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry
Published in Časopis lékařů českých (2016)“…Idiopathic pulmonary fibrosis (IPF) is a rare, progressive and usually fatal form of idiopathic interstitial pneumonia. IPF is characterized by failure of…”
Get more information
Journal Article